Zynex, Inc., through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. It offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation (TENS), and neuromuscular electrical stimulation (NMES) device; NeuroMove, an electromyography triggered electrical stimulation device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; and E-Wave, an NMES device. The company also supplies electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products; and distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, and LSO Back Braces for lumbar support. In addition, it offers CM-1500, a blood volume monitor device for monitoring central blood volume for use in operating and recovery rooms to detect blood loss during surgery and internal bleeding during recovery. The company provides its products for use in pain management and control; and stroke and spinal cord injury rehabilitation. Zynex, Inc. sells its products through direct sales force primarily in the United States. The company was founded in 1996 and is headquartered in Englewood, Colorado.
IPO Year:
Exchange: NASDAQ
Website: zynex.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/1/2025 | $3.70 | Neutral → Buy | Ladenburg Thalmann |
| 8/1/2025 | Buy → Neutral | H.C. Wainwright | |
| 3/12/2025 | $11.00 → $5.50 | Outperform → Sector Perform | RBC Capital Mkts |
| 3/12/2025 | Buy → Neutral | Ladenburg Thalmann | |
| 10/16/2023 | $13.00 | Outperform | RBC Capital Mkts |
| 1/6/2023 | $10.00 → $18.00 | Neutral → Overweight | Piper Sandler |
| 2/28/2022 | $15.50 → $10.00 | Buy | B. Riley Securities |
| 2/25/2022 | $22.00 → $20.00 | Buy | HC Wainwright & Co. |
| 7/30/2021 | $25.00 → $22.00 | Buy | HC Wainwright & Co. |
| 7/16/2021 | $19.50 | Neutral → Buy | B. Riley Securities |
Fastest customizable press release news feed in the world
ENGLEWOOD, Colo., Aug. 18, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced the arrival of newly appointed CEO, Steven Dyson, and the appointment of several new leaders at the Company. On June 30, 2025, the Company announced the Board's appointment of Steven Dyson as the incoming CEO. Since that time, Mr. Dyson and Thomas Sandgaard, the Chairman of the Board, have been actively working wi
ENGLEWOOD, Colo., July 31, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported its financial and operational results for the second quarter ended June 30, 2025. Management Commentary "In the second quarter of 2025, we completed two transformational events. First, we appointed Steven Dyson as our new CEO. Steven brings over 25 years of experience in the medical technology sector, primarily thro
ENGLEWOOD, Colo., July 22, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, will hold a conference call on Thursday, July 31, 2025 at 4:15 PM Eastern Time to discuss its financial results for the second quarter ended June 30, 2025. Financial results will be issued in a press release prior to the call. Zynex management will host the conference call, followed by a question and answer session. Date: Thursday
ENGLEWOOD, Colo., July 2, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced the Company received an update from Tricare that the temporary payment suspension will continue. "As we previously announced, we were notified of a temporary suspension of payments from our largest insurance customer, Tricare," said Thomas Sandgaard, President and CEO of Zynex. "We appealed the temporary suspension a
ENGLEWOOD, Colo., June 30, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in noninvasive medical devices for pain management, rehabilitation, and patient monitoring, today announced the appointment of Steven Dyson as Chief Executive Officer. His employment will begin on August 18, 2025. Thomas Sandgaard, Founder of Zynex and Chairman of the Board since the company's inception in 1996, will remain actively involved as Chairman and Chair of the Board's Technology Committee. Steven brings over 25 years of experience in the me
ENGLEWOOD, Colo., June 25, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of noninvasive medical devices for pain management, rehabilitation, and patient monitoring, today announced it has been awarded UK patent 2617515 for a multiparameter, noninvasive sepsis monitor. Sepsis is a life-threatening condition characterized by systemic inflammation and organ dysfunction caused by an infection. Over half of sepsis cases are contracted in hospitals and have a high mortality rate due to the difficult
ENGLEWOOD, Colo., May 12, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced it has submitted a 510(k) application to the U.S. Food and Drug Administration ("FDA") for its NiCO™, Noninvasive CO-Oximeter device. This submission marks a historic milestone in the evolution of pulse oximetry and a major breakthrough for the Company in its mission to improve the quality of care and patient outco
ENGLEWOOD, Colo., April 29, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported its financial and operational results for the first quarter ended March 31, 2025. Management Commentary "In the first quarter of 2025, we continued to see steady orders for our pain management and private-labeled rehabilitation products. Total orders decreased 3% year-over-year, but our sales force headcount was ap
ENGLEWOOD, Colo., April 22, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, will hold a conference call on Tuesday, April 29, 2025 at 4:15 PM Eastern Time to discuss its financial results for the first quarter ended March 31, 2025. Financial results will be issued in a press release prior to the call. Zynex management will host the conference call, followed by a question and answer session. Date: Tuesday
ENGLEWOOD, Colo., March 11, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported its financial and operational results for the fourth quarter and full year ended December 31, 2024. Key Highlights and Business Update FY 2024 orders increased 16% year-over-yearFY 2024 net revenue increased 4% to $192.4 millionFY 2024 net income of $3.0 million; Diluted EPS $0.09FY 2024 cash flow from operations of
Live finance-specific insights
ENGLEWOOD, Colo., July 31, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported its financial and operational results for the second quarter ended June 30, 2025. Management Commentary "In the second quarter of 2025, we completed two transformational events. First, we appointed Steven Dyson as our new CEO. Steven brings over 25 years of experience in the medical technology sector, primarily thro
ENGLEWOOD, Colo., July 22, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, will hold a conference call on Thursday, July 31, 2025 at 4:15 PM Eastern Time to discuss its financial results for the second quarter ended June 30, 2025. Financial results will be issued in a press release prior to the call. Zynex management will host the conference call, followed by a question and answer session. Date: Thursday
ENGLEWOOD, Colo., April 29, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported its financial and operational results for the first quarter ended March 31, 2025. Management Commentary "In the first quarter of 2025, we continued to see steady orders for our pain management and private-labeled rehabilitation products. Total orders decreased 3% year-over-year, but our sales force headcount was ap
ENGLEWOOD, Colo., April 22, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, will hold a conference call on Tuesday, April 29, 2025 at 4:15 PM Eastern Time to discuss its financial results for the first quarter ended March 31, 2025. Financial results will be issued in a press release prior to the call. Zynex management will host the conference call, followed by a question and answer session. Date: Tuesday
ENGLEWOOD, Colo., March 11, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported its financial and operational results for the fourth quarter and full year ended December 31, 2024. Key Highlights and Business Update FY 2024 orders increased 16% year-over-yearFY 2024 net revenue increased 4% to $192.4 millionFY 2024 net income of $3.0 million; Diluted EPS $0.09FY 2024 cash flow from operations of
ENGLEWOOD, Colo., March 3, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, will hold a conference call on Tuesday, March 11, 2025 at 4:15 PM Eastern Time to discuss its financial results for the fourth quarter and year ended December 31, 2024. Financial results will be issued in a press release prior to the call. Zynex management will host the conference call, followed by a question and answer session. Da
ENGLEWOOD, Colo., Oct. 24, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported its financial and operational results for the third quarter ended September 30, 2024. Key Third Quarter Highlights and Business Update Q3 2024 orders increased 13% year-over-year.Q3 2024 net revenue of $50.0 million.Q3 2024 net income of $2.4 million; Diluted EPS $0.07.Q3 2024 cash flow from operations of $7.1 millio
ENGLEWOOD, Colo., Oct. 16, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, will hold a conference call on Thursday, October 24, 2024 at 4:15 PM Eastern Time to discuss its financial results for the third quarter ended September 30, 2024. Financial results will be issued in a press release prior to the call. Zynex management will host the conference call, followed by a question and answer session. Date: T
Q2 2024 Revenue Increased 11% to $49.9 Million ENGLEWOOD, Colo., July 25, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported its financial and operational results for the second quarter ended June 30, 2024. Key Second Quarter Highlights and Business Update Q2 2024 orders increased 20% year-over-year, the highest number of orders in Company history for the ninth consecutive quarter.Q2 2024 reve
ENGLEWOOD, Colo., July 17, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, will hold a conference call on Thursday, July 25, 2024 at 4:15 PM Eastern Time to discuss its financial results for the second quarter ended June 30, 2024. Financial results will be issued in a press release prior to the call. Zynex management will host the conference call, followed by a question and answer session. Date: Thursday
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - ZYNEX INC (0000846475) (Issuer)
8-K - ZYNEX INC (0000846475) (Filer)
10-Q - ZYNEX INC (0000846475) (Filer)
8-K - ZYNEX INC (0000846475) (Filer)
8-K - ZYNEX INC (0000846475) (Filer)
10-Q/A - ZYNEX INC (0000846475) (Filer)
10-K/A - ZYNEX INC (0000846475) (Filer)
8-K - ZYNEX INC (0000846475) (Filer)
8-K - ZYNEX INC (0000846475) (Filer)
8-K - ZYNEX INC (0000846475) (Filer)
8-K - ZYNEX INC (0000846475) (Filer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
3 - ZYNEX INC (0000846475) (Issuer)
4 - ZYNEX INC (0000846475) (Issuer)
4 - ZYNEX INC (0000846475) (Issuer)
4 - ZYNEX INC (0000846475) (Issuer)
4 - ZYNEX INC (0000846475) (Issuer)
4 - ZYNEX INC (0000846475) (Issuer)
4 - ZYNEX INC (0000846475) (Issuer)
4 - ZYNEX INC (0000846475) (Issuer)
4 - ZYNEX INC (0000846475) (Issuer)
4 - ZYNEX INC (0000846475) (Issuer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Ladenburg Thalmann upgraded Zynex from Neutral to Buy and set a new price target of $3.70
H.C. Wainwright downgraded Zynex from Buy to Neutral
RBC Capital Mkts downgraded Zynex from Outperform to Sector Perform and set a new price target of $5.50 from $11.00 previously
Ladenburg Thalmann downgraded Zynex from Buy to Neutral
RBC Capital Mkts initiated coverage of Zynex with a rating of Outperform and set a new price target of $13.00
Piper Sandler upgraded Zynex from Neutral to Overweight and set a new price target of $18.00 from $10.00 previously
B. Riley Securities reiterated coverage of Zynex with a rating of Buy and set a new price target of $10.00 from $15.50 previously
HC Wainwright & Co. reiterated coverage of Zynex with a rating of Buy and set a new price target of $20.00 from $22.00 previously
HC Wainwright & Co. reiterated coverage of Zynex with a rating of Buy and set a new price target of $22.00 from $25.00 previously
B. Riley Securities upgraded Zynex from Neutral to Buy and set a new price target of $19.50
Live Leadership Updates
ENGLEWOOD, Colo., Aug. 18, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced the arrival of newly appointed CEO, Steven Dyson, and the appointment of several new leaders at the Company. On June 30, 2025, the Company announced the Board's appointment of Steven Dyson as the incoming CEO. Since that time, Mr. Dyson and Thomas Sandgaard, the Chairman of the Board, have been actively working wi
ENGLEWOOD, Colo., June 30, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in noninvasive medical devices for pain management, rehabilitation, and patient monitoring, today announced the appointment of Steven Dyson as Chief Executive Officer. His employment will begin on August 18, 2025. Thomas Sandgaard, Founder of Zynex and Chairman of the Board since the company's inception in 1996, will remain actively involved as Chairman and Chair of the Board's Technology Committee. Steven brings over 25 years of experience in the me
ENGLEWOOD, Colo., Dec. 3, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI) ("Zynex", "ZMS", "we" or the "Company"), an innovative medical technology company specializing in the manufacture and sale of noninvasive medical devices for pain management, rehabilitation, and patient monitoring, today announced its membership in the Collaborative Community of the independently led Open Oximetry Project as an industry member. The Open Oximetry Project, an initiative led by the University of California, San Francisco's Center for Health Equity in Surgery and Anesthesia, is dedicated to i
ENGLEWOOD, Colo., June 13, 2022 /PRNewswire/ -- Zynex, Inc. ("Zynex or the "Company) (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced that it has changed its auditors from Plante & Moran, PLLC ("Plante Moran") as the Company's independent registered accounting firm to Marcum LLP effective June 13, 2022. The appointment of Marcum LLP was made after careful consideration and an evaluation process by the Company and approved by the Board of Directors and the Audit Committee of the Company.
ENGLEWOOD, Colo., April 20, 2021 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics today announced that it has hired Donald Gregg as the Vice President of Sales and Operations of its Monitoring Solutions Division. In this position, Donald will lead operations, sales, marketing and product development of the Monitoring Solution Division including the production and launch of the CM-1500 Blood Volume Monitor which was granted 510(k) clearance by the U.S. Food and Drug Administration in 2020.
ENGLEWOOD, Colo., Jan. 28, 2021 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics today announced that it has promoted Anna Lucsok to Chief Operating Officer (COO) of Zynex Medical, its pain management division. Joseph Papandrea previously held the position of COO. Thomas Sandgaard, founder and CEO said: "I would personally like to thank Joseph for his leadership and contributions. We wish him nothing but the best in the future. I would also like to congratulate Anna on a well-deserved prom
This live feed shows all institutional transactions in real time.
SC 13D/A - ZYNEX INC (0000846475) (Subject)